13 Results for "

rat insulinoma cells

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "rat insulinoma cells" in MCE Product Catalog:

77
77 Publications Verification
Cat. No.: HY-B0470
CAS No.: 1405-10-3
Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin sulfate inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin sulfate depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin sulfate can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13529
CAS No.: 1234703-40-2
Purity:  ≥98.0%
Synonyms: LY2608204; SY-004
Target:  

Glucokinase

Research Areas:  

Metabolic Disease

Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC50 of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with an EC50 of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-150520
CAS No.: 1404-04-2
Research Areas:  

Infection Cancer

Neomycin, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin is a known phospholipase C (PLC) inhibitor. Neomycin potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P10927A
Synonyms: BRINP2-related peptide TFA
Target:  

PKA AP-1

Research Areas:  

Metabolic Disease

BRP (BRINP2-related peptide) TFA is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP TFA induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP TFA exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP TFA is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP TFA is applicable to obesity-related research .
loading...
    loading...
Cat. No.: HY-P10927
Synonyms: BRINP2-related peptide
Target:  

AP-1 PKA

Research Areas:  

Metabolic Disease

BRP is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP is applicable to obesity-related research .
loading...
    loading...
Cat. No.: HY-N6005
CAS No.: 3843-74-1
Methyl caffeate is a phenylpropanoid, antibacterial agent, and Apoptosis-inducing agent. Methyl caffeate can be isolated from the flowers of peach Prunus persica (L.). Methyl caffeate upregulates the expression of pro-apoptotic proteins Bid, Bax and p53, and downregulates the expression of anti-apoptotic protein BCL-2. Methyl caffeate downregulates SASP factors. Methyl caffeate enhances glucose-stimulated insulin secretion. Methyl caffeate inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, fungi, and Mycobacterium tuberculosis strains. Methyl caffeate can be used in studies related to breast cancer, type 2 diabetes, and tuberculosis .
loading...
    loading...
Cat. No.: HY-176040
CAS No.: 956783-34-9
Target:  

IRE1 Amyloid-β

IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells .
loading...
    loading...
Cat. No.: HY-121872
CAS No.: 222315-88-0
Purity:  ≥95.0%
Research Areas:  

Neurological Disease

DP-b99 is a blood-brain barrier-permeable inhibitor of CYP2C9 and MMP-9, with a Ki value of 4.655 μM against CYP2C9. DP-b99 inhibits CYP2C9 via apparent non-competitive inhibition, mainly chelates pathological Zn 2+ in the membrane environment, attenuates the elevation of intracellular Zn 2+ and Ca 2+ levels, delays seizure onset and reduces seizure severity, and also prevents MMP-9-dependent dendritic spine remodeling, β-dystroglycan cleavage and gelatinase activity. DP-b99 can be used in the research of acute ischemic stroke, epileptogenesis and stroke .
loading...
    loading...
Cat. No.: HY-148235
CAS No.: 858097-86-6
Research Areas:  

Metabolic Disease

TP-051, a chemical probe, is a potent FFAR1 agonist with an Ki value of 16 nM for human FFAR1. TP-051 can increase insulin secretion in rat insulinoma cells. TP-051 can be used to research type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P1544
CAS No.: 94071-26-8
Cerebellin is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin can be used in neurological research .
loading...
    loading...
Cat. No.: HY-170593
CAS No.: 3067202-14-3
Research Areas:  

Metabolic Disease

ChREBPα/14-3-3 regulator-1 is a molecular glue that selectively stabilizes ChREBPα/14-3-3 PPI, with an EC50 of 3.8 μM. ChREBPα/14-3-3 regulator-1 sequesters ChREBPα in the cytoplasm, inhibits ChREBPβ and TXNIP responses, reduces glucolipotoxicity-induced β-cell death, and maintains β-cell identity and function. ChREBPα/14-3-3 regulator-1 can be used in studies related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P11945
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease Cancer

NOTA-MAL-Cys39-Exendin-4 is an imaging agent and radiotracer precursor targeting GLP-1R. NOTA-MAL-Cys39-Exendin-4 binds specifically to GLP-1R and is rapidly cleared by the liver and spleen during the blood pool phase. NOTA-MAL-Cys39-Exendin-4 can be efficiently radiolabeled with gallium-68 to form a stable radiotracer with high radiochemical purity. NOTA-MAL-Cys39-Exendin-4 is applicable to research related to insulinomas .
loading...
    loading...
Cat. No.: HY-183955
CAS No.: 2041071-54-7
Target:  

DYRK GSK-3

GNF7156 is a DYRK1A/GSK3B inhibitor, IC50 values of 100 nM for DYRK1A and 40 nM for GSK3B. GNF7156 inhibits DYRK1A and GSK3B kinase activity and induces NFAT nuclear retention. GNF7156 stimulates beta-cell cycle entry and division and maintains insulin secretory capacity. GNF7156 can be used for the research of type 1 diabetes, and type 2 diabetes .
loading...
    loading...
  • 1